Generate Biomedicines priced a $400M IPO at $16/share. Despite an asthma lead program, investors are watching the platform’s oncology reach. The IPO is a real-time signal about what public-market investors are currently willing to fund: platform narratives that claim to compress discovery timelines and generate multiple modalities, including assets relevant to cancer. At the same time, IPO coverage has highlighted a key diligence issue for AI-centric biotech valuations: industry observers still point out that a fully AI-discovered drug has not yet achieved U.S. Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under the ticker “GENB.” In February 2026, the offering was described as the largest biotechnology IPO to date for the year and part of an unusually active month for biotech listings. In addition to IPO proceeds, industry reporting cited more than $800 million in prior venture financing and approximately $110 million in collaboration payments from Amgen and Novartis tied to the company’s platform.

Original title: “Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus - OncoDaily”

Learn how to lower your cancer risk and what CDC is doing to prevent and control cancer.

Original title: “Cancer”

The Denton site is part of a network of manufacturing plants Novartis is building across the U.S. to make cancer drugs that must be shipped to patients quickly.

Original title: “Novartis Names Texas City as Location of Its 5th US Radiopharmaceutical Facility”

CDC offers resources about cancer in a variety of formats.

Original title: “Resource Library”

Billions of dollars’ worth of cancer drugs are discarded each year. Manufacturers must refund Medicare for some of this waste. A data-driven approach offers a practical path to greater efficiency.

Original title: “Cut Down on Oncology Drug Waste With Better Forecasting”

Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts Bloomberg Intelligence, translating to some $22 billion more in revenue.

Original title: “Merck’s Keytruda Likely Has a Few Extra Years of Dominance, With Billions on the Line”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled The National Firefighter Registry for Cancer (NFR). In accordance with the Firefight

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.

Original title: “Merck to split cancer, specialty drug businesses in leadership shakeup”

Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses.

Original title: “Grail’s multi-cancer early detection test misses study goal”

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. | Gilead penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. Gilead penned a $1.5 billion cancer deal. A cell therapy firm could end a biotech IPO drought in Tokyo. Novo faces more GLP-1 competition in China. Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. Novo Nordisk faces increased GLP-1 competition in China. Japanese cell therapy company Innovacell aims to go public on the Tokyo Stock Exchange on Feb. 24. With a regenerative therapy for urge fecal incontinence in phase 3 development, the company plans to initially offer 8.4 million shares at a price of 1,350 Japanese yen apiece. There were no biotech IPOs on Tokyo's stock exchange last year. 2. Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering

Original title: “Fierce Pharma Asia—Gilead's synthetic lethality deal; A Tokyo biotech IPO; Novo’s Ozempic China sales dip”

therapeutic vaccination for active induction of t cell immunity against cancer ready for a rich harvest after 40 years

Original title: “Therapeutic vaccination for active induction of T cell immunity against cancer, ready for a rich harvest after 40 years.”

Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.

Original title: “Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand”

Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for Europe.

Original title: “Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs”

priority european strategies for sustainable access to high quality genetic counselling in cancer a delphi study

Original title: “Priority European strategies for sustainable access to high-quality genetic counselling in cancer: A Delphi study.”

A follow-up analysis of a clinical trial that evaluated anti-PD-1 therapy in patients with cancer who are living with HIV provides mechanistic insights into transcriptomic, cellular and cytokine changes related to immune checkpoint inhibitor treatment and identifies a signature associated with ... A follow-up analysis of a clinical trial that evaluated anti-PD-1 therapy in patients with cancer who are living with HIV provides mechanistic insights into transcriptomic, cellular and cytokine changes related to immune checkpoint inhibitor treatment and identifies a signature associated with clinical response. Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. Anti-PD-1 therapies have reduced the HIV reservoir in people living with HIV (PLWH) and cancer; however, the individuals who benefit and the mechanisms driving reservoir reduction remain unclear. Nature Medicine - A follow-up analysis of a clinical trial that evaluated anti-PD-1 therapy in patients with cancer who are living with HIV provides mechanistic insights into transcriptomic,... We performed a prespecified exploratory, longitudinal multiomic profiling of 30 PLWH (29 males and one female) with cancer in the phase 1 CITN-12 clinical trial, in which pembrolizumab was evaluated for safety and preliminary antitumor activity. The therapy was generally well tolerated, with most adverse events graded 1–2 and objective antitumor response observed in five participants (one complete response and four partial responses). Within 24 hours of treatment, we observed an expansion of proliferating HIV-specific effector CD8+ T cells and a decline in plasma TGFβ.

Original title: “Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy | Nature Medicine”

preclinical evaluation of 68 ga labeled gsk3326595 for prmt5 expression with micropet ct in pan cancer

Original title: “Preclinical Evaluation of (68)Ga-Labeled GSK3326595 for PRMT5 Expression with microPET-CT in Pan-Cancer.”

As next-generation antibody-drug conjugates reshape cancer care, digital pathology and artificial intelligence are transforming how HER2 is measured. The advances aim to help clinicians identify low and ultra-low expressors, match patients to the right therapies and make more precise treatment decisions.

Original title: “HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs”

sensitive detection of cancer antigens enabled by user defined peptide libraries

Original title: “Sensitive detection of cancer antigens enabled by user-defined peptide libraries.”

During the past decade, a total of 410 new molecular entities have been approved by the US Food and Drug Administration (FDA), with a steady growth of 6.5% in the US. In Europe, 9–75% of approved anticancer drugs were granted at least one expedited approval program. Various expedited pathways have also been implemented worldwide to address underrepresented medical needs rapidly. China has adapted several expedited approval programs, including breakthrough therapy designation, priority review, and conditional approval, to keep up with the growth in pharmaceutical development.

Original title: “An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020 - ScienceDirect”

M&amp;A has been steady in 2024. We count <strong>47 private &amp; public deals to date totaling $53 billion</strong>. 15 have been &gt;$1 billion with cancer, rare disease &amp; cell therapies some of the areas of interest.

Original title: “Biotech IPOs and M&As in 2020”